Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1317 of 5804
-
AI could help avoid unnecessary lung procedures
Diagnosis OngoingThis clinical trial studies whether a biomarker platform, the Virtual Nodule Clinic, can be used for the management of lung (pulmonary) nodules that are not clearly non-cancerous (benign) or clearly cancerous (malignant) (indeterminate pulmonary nodules \[IPNs\]). The management …
Phase: NA • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
Hospital program aims to protect thousands of kids from flu
⭐️ VACCINE ⭐️ Recruiting nowThis study plans to learn more about whether a stakeholder-informed, standardized inpatient vaccination program will increase influenza vaccination rates of hospitalized children across US pediatric health systems. The first part of the study is to form a multidisciplinary team o…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowAn open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Crohn's patients: switch drug or up dose? new trial seeks answers
Disease control Recruiting nowA substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor (TNF) agents maintenance therapy. The optimal intervention in patients with secondary loss-of-respon…
Phase: PHASE4 • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Donor cell boost aims to rescue failed stem cell transplants
Disease control Recruiting nowThe proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for young sarcoma patients: experimental drug combo targets tough tumors
Disease control TerminatedBackground: The drug PEN-866 can remain in tumor cells longer than it does in normal cells. It also may be more effective than other drugs at treating Ewing sarcoma and rhabdomyosarcoma. Researchers want to learn if combining PEN-866 with other drugs can treat certain cancers in…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
CBD put to the test as a smoking reduction aid
Disease control Recruiting nowThe goal of this research is to evaluate the efficacy of cannabidiol (CBD) in reducing cigarette smoking. Although there are safe and effective treatments for smoking cessation, not everyone who attempts smoking cessation is successful, even with these treatments. Relapse rates a…
Phase: PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New antibody injection targets advanced cancers in early human trial
Disease control Recruiting nowThis study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with locally advanced or metastatic breast cance…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Weight-Loss drug tirzepatide tested to boost breast cancer outcomes
Disease control Recruiting nowThis clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolera…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a new eye inside arteries predict heart attacks in diabetics?
Knowledge-focused Recruiting nowTo evaluate the correlation between maxLCBI4mm/FCTmin(a new index of lipid plaque based on NIRS-OCT technology) and fiber cap thickness , and the prognosis of patients, providing a new quantitative index for early, accurate and comprehensive identification of vulnerable plaques, …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
New drug AZD0780 aims to lower blood pressure in heart patients
Disease control CompletedThis is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory blood pressure monitoring (ABPM) in participants w…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Plant pigment could soothe Radiation's harsh side effect in blood cancer treatment
Symptom relief Recruiting nowThe goal of this phase II, single-arm interventional clinical trial is to evaluate whether oral sodium copper chlorophyllin (CHL) can reduce the frequency and severity of oral mucositis in patients aged 12-65 years undergoing myeloablative total body irradiation (TBI) as part of …
Phase: PHASE2 • Sponsor: Tata Memorial Centre • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
New pill could tame Crohn's Flare-Ups
Disease control Recruiting nowThis study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to se…
Phase: PHASE2 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can a diabetes drug boost weight loss after bypass surgery?
Disease control ENROLLING_BY_INVITATIONThe goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI \> 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirze…
Phase: PHASE2, PHASE3 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for Hard-to-Treat liver disease: steroid combo trial launches
Disease control ENROLLING_BY_INVITATIONAbout 1/3 of patients with primary biliary cholangitis (PBC) exhibit moderate to severe interface hepatitis, and this group of patients have poor response to UDCA treatment. However, as it is not yet sufficient to diagnose autoimmune hepatitis or overlap syndrome, it is difficult…
Phase: PHASE2, PHASE3 • Sponsor: Han Ying • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for kidney patients: early budesonide may slow IgA nephropathy
Disease control Recruiting nowTo observe of the efficacy and safety of early initiation of budesonide enteric coated capsules in the treatment of primary IgA nephropathy.
Sponsor: Sichuan Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug duo aims to control rare lymphoma without chemotherapy
Disease control Recruiting nowThis is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Zanubrutinib in combination with Rituximab as a first-line treatment for patients with mucosa-associated lymphoid tissue (MALT) extranodal marginal zone lymphoma.
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New study tests migraine drug as attack stopper
Symptom relief Recruiting nowA perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature…
Sponsor: University of Florence • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New shot aims to control Hard-to-Treat bone marrow cancer
Disease control Recruiting nowThis is a first-in-human study of SAR446523 conducted in patients with RRMM. The study consists of two parts: Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 will be explored to determine the maximum administered dose (MAD), maximum tolerate…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a blood pressure drug combo tame panic attacks?
Disease control TerminatedThe purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.
Phase: PHASE2 • Sponsor: HB BioTech, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC